SGCG and cancer: We discovered that APR-246 could induce type I and/or type III IFN expression in a number of mtp53 cancer cell lines (Fig. 5b) and repress negative immune checkpoint molecules in a number of mtp53 cancer cell lines (Figs. 5a and S4a), which potentially increases the sensitivity of tumour cells to CD8+ T cells.